Amphotericin - lipid associated
Spectrum Of Activity
Liposomal (Ambisome): IV: 3 to 5mg/kg/DAY given as a single daily doseLipid Complex (Abelcet): IV: 2.5 to 5 mg/kg/DAY given as a single daily dose.
Liposomal (Ambisome): IV: 3 to 5mg/kg/DAY given as a single daily dose. Lipid Complex (Abelcet): IV 2 to 5mg/kg/DAY given as a single daily dose.
Contact pharmacy for more information regarding use in renal impairment.
Fungicidal therapy of yeast/fungus/mold infection (not for use in urinary tract infection)
Invasive candidiasis, aspergillosis, cryptococcosis
Induction therapy for dimorphic fungii (cocci, blasto, histo)
Renal function, fluid status, serum electrolytes (K, Mg).
Liver enzymes, CBC with differential.
Infusion related symptoms: fever/rigors/N/V/headache
Electrolyte abnormalities - hypokalemia and hypomagnesemia, loss of bicarb
Enhance nephrotoxic effect with concomitant use of other nephrotoxins - use should be minimized during amphotericin therapy.
Lipid formulations of AmB (Ambisome, Abelcet) are NOT interchangable.
Premedication with acetaminophen, diphenhydramine, or hydrocortisone for infusion related symptoms.
Antimicrobial class: Antifungal - polyene - Lipid formulations (designed to minimize toxicity)
Average serum half life:
No pediatric data.
Liposomal: Adults: 100-153 hours (terminal half life).
Lipid Complex: Adults: 173 hours (terminal half life).
Route of Elimination: Lipid Complex: 0.9% of drug excreted in urine over 24h; effects of hepatic and renal impairment on drug disposition are unknown.